Plain-English translation of NCT07517185 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The HiHat trial is testing a new treatment approach for people with relapsing-remitting multiple sclerosis (a form of MS where symptoms come and go). You would receive two medications—rituximab and cladribine—given one after the other in a specific sequence. The study wants to see if this combination is safe and whether it helps reduce MS activity like relapses and brain lesions.
Currently, doctors treat MS with single medications, but many patients still experience relapses and disease progression. This trial explores whether using two different immune-targeting medications together, started early in the disease, might work better to control MS and prevent future damage.
You likely qualify if…
You likely don't qualify if…
You would visit the research clinic multiple times over 24 months. You would receive two cycles of the first medication (rituximab) given as infusions two weeks apart, followed by two cycles of the second medication (cladribine) taken as pills for three days at a time, spaced one month apart. Throughout the 24 months, you would have regular check-ins including blood tests, MRI brain scans, and assessments of your symptoms and quality of life to monitor how well the treatment is working and whether you experience any side effects.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
Sweden